AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis

NASDAQ:FOLD • US03152W1099

14.34 USD
-0.02 (-0.14%)
At close: Feb 25, 2026
14.36 USD
+0.02 (+0.14%)
After Hours: 2/25/2026, 8:13:27 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

FOLD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. FOLD has only an average score on both its financial health and profitability. FOLD has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year FOLD has reported negative net income.
  • In the past year FOLD had a positive cash flow from operations.
  • In the past 5 years FOLD always reported negative net income.
  • In the past 5 years FOLD always reported negative operating cash flow.
FOLD Yearly Net Income VS EBIT VS OCF VS FCFFOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • FOLD has a better Return On Assets (-1.62%) than 87.72% of its industry peers.
  • FOLD's Return On Equity of -6.10% is amongst the best of the industry. FOLD outperforms 88.87% of its industry peers.
  • The Return On Invested Capital of FOLD (4.07%) is better than 90.79% of its industry peers.
Industry RankSector Rank
ROA -1.62%
ROE -6.1%
ROIC 4.07%
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
FOLD Yearly ROA, ROE, ROICFOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • FOLD has a Operating Margin of 5.77%. This is amongst the best in the industry. FOLD outperforms 89.64% of its industry peers.
  • FOLD has a Gross Margin of 89.77%. This is amongst the best in the industry. FOLD outperforms 91.94% of its industry peers.
  • In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
Industry RankSector Rank
OM 5.77%
PM (TTM) N/A
GM 89.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
FOLD Yearly Profit, Operating, Gross MarginsFOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), FOLD is destroying value.
  • There is no outstanding debt for FOLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FOLD Yearly Shares OutstandingFOLD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
FOLD Yearly Total Debt VS Total AssetsFOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 1.13, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
  • With a decent Altman-Z score value of 1.13, FOLD is doing good in the industry, outperforming 63.34% of the companies in the same industry.
  • The Debt to FCF ratio of FOLD is 40.45, which is on the high side as it means it would take FOLD, 40.45 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of FOLD (40.45) is better than 89.64% of its industry peers.
  • A Debt/Equity ratio of 1.70 is on the high side and indicates that FOLD has dependencies on debt financing.
  • The Debt to Equity ratio of FOLD (1.70) is worse than 77.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.7
Debt/FCF 40.45
Altman-Z 1.13
ROIC/WACC0.45
WACC8.95%
FOLD Yearly LT Debt VS Equity VS FCFFOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • FOLD has a Current Ratio of 2.99. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
  • FOLD has a worse Current ratio (2.99) than 64.49% of its industry peers.
  • FOLD has a Quick Ratio of 2.09. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
  • FOLD has a worse Quick ratio (2.09) than 73.70% of its industry peers.
Industry RankSector Rank
Current Ratio 2.99
Quick Ratio 2.09
FOLD Yearly Current Assets VS Current LiabilitesFOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.33% over the past year.
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%23.72%

3.2 Future

  • The Earnings Per Share is expected to grow by 107.92% on average over the next years. This is a very strong growth
  • FOLD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.18% yearly.
EPS Next Y534.7%
EPS Next 2Y230.38%
EPS Next 3Y175.47%
EPS Next 5Y107.92%
Revenue Next Year18.91%
Revenue Next 2Y18.63%
Revenue Next 3Y19.2%
Revenue Next 5Y18.18%

3.3 Evolution

FOLD Yearly Revenue VS EstimatesFOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
FOLD Yearly EPS VS EstimatesFOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 43.98 indicates a quite expensive valuation of FOLD.
  • 90.98% of the companies in the same industry are more expensive than FOLD, based on the Price/Forward Earnings ratio.
  • FOLD is valuated expensively when we compare the Price/Forward Earnings ratio to 28.03, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 43.98
FOLD Price Earnings VS Forward Price EarningsFOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

  • FOLD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. FOLD is cheaper than 89.83% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, FOLD is valued cheaply inside the industry as 89.83% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 464.52
EV/EBITDA 108.18
FOLD Per share dataFOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • FOLD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as FOLD's earnings are expected to grow with 175.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y230.38%
EPS Next 3Y175.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • FOLD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMICUS THERAPEUTICS INC

NASDAQ:FOLD (2/25/2026, 8:13:27 PM)

After market: 14.36 +0.02 (+0.14%)

14.34

-0.02 (-0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20
Earnings (Next)04-29
Inst Owners101.15%
Inst Owner Change1.94%
Ins Owners0.55%
Ins Owner Change-7.56%
Market Cap4.50B
Revenue(TTM)N/A
Net Income(TTM)-14.06M
Analysts71.43
Price Target15.81 (10.25%)
Short Float %5.91%
Short Ratio1.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.12%
Min EPS beat(2)41.73%
Max EPS beat(2)52.51%
EPS beat(4)3
Avg EPS beat(4)76.91%
Min EPS beat(4)-26.06%
Max EPS beat(4)239.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.57%
Min Revenue beat(2)0.02%
Max Revenue beat(2)3.12%
Revenue beat(4)2
Avg Revenue beat(4)-1.83%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)4
Avg Revenue beat(8)-0.79%
Revenue beat(12)8
Avg Revenue beat(12)-0.1%
Revenue beat(16)9
Avg Revenue beat(16)-1.08%
PT rev (1m)-1.36%
PT rev (3m)-3.12%
EPS NQ rev (1m)2.97%
EPS NQ rev (3m)41.22%
EPS NY rev (1m)23.05%
EPS NY rev (3m)69.69%
Revenue NQ rev (1m)0.51%
Revenue NQ rev (3m)0.32%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)0.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 43.98
P/S 7.52
P/FCF 464.52
P/OCF 346.92
P/B 19.54
P/tB 251.71
EV/EBITDA 108.18
EPS(TTM)-0.08
EYN/A
EPS(NY)0.33
Fwd EY2.27%
FCF(TTM)0.03
FCFY0.22%
OCF(TTM)0.04
OCFY0.29%
SpS1.91
BVpS0.73
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.62%
ROE -6.1%
ROCE 5.15%
ROIC 4.07%
ROICexc 6.72%
ROICexgc 14.09%
OM 5.77%
PM (TTM) N/A
GM 89.77%
FCFM 1.62%
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 1.7
Debt/FCF 40.45
Debt/EBITDA 9.31
Cap/Depr 43.2%
Cap/Sales 0.55%
Interest Coverage 0.78
Cash Conversion 30.81%
Profit Quality N/A
Current Ratio 2.99
Quick Ratio 2.09
Altman-Z 1.13
F-Score5
WACC8.95%
ROIC/WACC0.45
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y534.7%
EPS Next 2Y230.38%
EPS Next 3Y175.47%
EPS Next 5Y107.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%23.72%
Revenue Next Year18.91%
Revenue Next 2Y18.63%
Revenue Next 3Y19.2%
Revenue Next 5Y18.18%
EBIT growth 1Y139.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.5%
EBIT Next 3Y90.97%
EBIT Next 5YN/A
FCF growth 1Y105.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y108.46%
OCF growth 3YN/A
OCF growth 5YN/A

AMICUS THERAPEUTICS INC / FOLD FAQ

What is the fundamental rating for FOLD stock?

ChartMill assigns a fundamental rating of 4 / 10 to FOLD.


What is the valuation status for FOLD stock?

ChartMill assigns a valuation rating of 5 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.


Can you provide the profitability details for AMICUS THERAPEUTICS INC?

AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.


What is the expected EPS growth for AMICUS THERAPEUTICS INC (FOLD) stock?

The Earnings per Share (EPS) of AMICUS THERAPEUTICS INC (FOLD) is expected to grow by 534.7% in the next year.